BriefCase-Quantification
Aidoc Medical, Ltd. • Radiology • 11/08/2023
Device Purpose
The BriefCase-Quantification software is designed to assist medical specialists by employing an AI-driven, deep-learning algorithm to automatically measure the maximum axial diameter of the abdominal aorta from contrast-enhanced CT DICOM images. Its methodology relies on cloud-based processing and provides an adjunctive quantitative assessment intended to streamline radiological workflow, with performance validated by a mean absolute error of 1.95 mm in a multicenter study.
Summary
BriefCase-Quantification by Aidoc Medical, Ltd. is a cloud-based radiological image management and processing software designed to assist medical specialists in analyzing CT exams with contrast of the abdominal aorta in adults (18+). Its primary function is to provide an automated measurement of the maximum abdominal aortic axial diameter for normal and aneurysmal aortas, excluding post-operative cases. The software utilizes an artificial intelligence, deep-learning algorithm that processes filtered DICOM images chronologically. After AI processing, the system generates a preview image annotated with the diameter measurement, which is then sent to an image review software and PACS for user review, emphasizing that these measurements are unofficial and require confirmation by a radiologist. The core science of BriefCase-Quantification lies in its AI-driven algorithm that identifies and measures the abdominal aorta from CT scan series. The device's performance was validated in a retrospective, blinded, multicenter study involving 160 cases from six US clinical sites. The study compared the software's measurements against a ground truth established by three board-certified radiologists. The primary endpoint was successfully achieved, with the software demonstrating a mean absolute error of 1.95 mm (95% CI: 1.59 mm, 2.32 mm) compared to the ground truth. This performance was deemed comparable to a reference device, supporting its utility as an aid in quantitative image analysis, though not as a standalone diagnostic tool.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the algorithm differentiate between normal and aneurysmal abdominal aortas, and what is its sensitivity and specificity for detecting aneurysms based on the measured diameter?; What were the specific criteria for case selection in the pivotal study, particularly regarding the range of aortic diameters and the prevalence of aneurysmal versus normal aortas?; Given the mean absolute error of 1.95 mm, what is the clinical impact of this potential measurement discrepancy on patient management, especially for aortas near critical diameter thresholds for intervention?; How does the software's performance vary across different CT scanner manufacturers (Siemens, GE, Philips, Toshiba) and image reconstruction techniques beyond what was detailed in the pivotal study summary?; Beyond maximum axial diameter, does the BriefCase-Quantification software offer or plan to offer any other morphological assessments of the abdominal aorta, such as length, tortuosity, or thrombus burden?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly